KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation
Summary: Oncogenic KRAS mutations are prevalent in colorectal cancer (CRC) and linked to poor prognosis and therapeutic resistance. Emerging evidence suggests that specific KRAS mutations differentially influence treatment responses. In this study, we generate isogenic Apc-null mouse colon epithelia...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | Cell Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211124725002153 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850099472921526272 |
|---|---|
| author | Konstantin Budagyan Alexa C. Cannon Adam Chatoff Dorothy Benton Alison M. Kurimchak Daniela Araiza-Olivera Anastasiia Gerasimova Nathaniel W. Snyder James S. Duncan Cristina Uribe-Alvarez Jonathan Chernoff |
| author_facet | Konstantin Budagyan Alexa C. Cannon Adam Chatoff Dorothy Benton Alison M. Kurimchak Daniela Araiza-Olivera Anastasiia Gerasimova Nathaniel W. Snyder James S. Duncan Cristina Uribe-Alvarez Jonathan Chernoff |
| author_sort | Konstantin Budagyan |
| collection | DOAJ |
| description | Summary: Oncogenic KRAS mutations are prevalent in colorectal cancer (CRC) and linked to poor prognosis and therapeutic resistance. Emerging evidence suggests that specific KRAS mutations differentially influence treatment responses. In this study, we generate isogenic Apc-null mouse colon epithelial cells with four common KRAS mutations. Transcriptomic and proteomic analyses reveal significant enrichment of cholesterol and lipid metabolism pathways in KRAS G12V cells, driven by increased SREBP1 expression and mTORC1 activation. Furthermore, KRAS G12V cells exhibit elevated ACSS2 expression and greater dependence on ACSS2 for proliferative advantage compared to other mutants. Inhibition of ACSS2 uniquely sensitizes KRAS G12V cells to MEK inhibition, highlighting a distinct therapeutic vulnerability. Finally, ACSS2 plays a critical role in early KRAS G12V adenoma development, unlike in KRAS G12D adenomas. These findings highlight mutation-specific metabolic reprogramming in KRAS-driven CRC and identify ACSS2 as a potential therapeutic target. |
| format | Article |
| id | doaj-art-a7f35dc952584589afe047a8b9bef4bd |
| institution | DOAJ |
| issn | 2211-1247 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cell Reports |
| spelling | doaj-art-a7f35dc952584589afe047a8b9bef4bd2025-08-20T02:40:29ZengElsevierCell Reports2211-12472025-04-0144411544410.1016/j.celrep.2025.115444KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formationKonstantin Budagyan0Alexa C. Cannon1Adam Chatoff2Dorothy Benton3Alison M. Kurimchak4Daniela Araiza-Olivera5Anastasiia Gerasimova6Nathaniel W. Snyder7James S. Duncan8Cristina Uribe-Alvarez9Jonathan Chernoff10Department of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, PA, USADepartment of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, PA, USADepartment of Cancer & Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USADepartment of Biochemistry & Molecular Biology, Drexel University College of Medicine, Philadelphia, PA, USACancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USACancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USACancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USADepartment of Cancer & Cellular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; Cancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USACancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USACancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA; Corresponding authorCancer Signaling & Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA; Corresponding authorSummary: Oncogenic KRAS mutations are prevalent in colorectal cancer (CRC) and linked to poor prognosis and therapeutic resistance. Emerging evidence suggests that specific KRAS mutations differentially influence treatment responses. In this study, we generate isogenic Apc-null mouse colon epithelial cells with four common KRAS mutations. Transcriptomic and proteomic analyses reveal significant enrichment of cholesterol and lipid metabolism pathways in KRAS G12V cells, driven by increased SREBP1 expression and mTORC1 activation. Furthermore, KRAS G12V cells exhibit elevated ACSS2 expression and greater dependence on ACSS2 for proliferative advantage compared to other mutants. Inhibition of ACSS2 uniquely sensitizes KRAS G12V cells to MEK inhibition, highlighting a distinct therapeutic vulnerability. Finally, ACSS2 plays a critical role in early KRAS G12V adenoma development, unlike in KRAS G12D adenomas. These findings highlight mutation-specific metabolic reprogramming in KRAS-driven CRC and identify ACSS2 as a potential therapeutic target.http://www.sciencedirect.com/science/article/pii/S2211124725002153CP: Cancer |
| spellingShingle | Konstantin Budagyan Alexa C. Cannon Adam Chatoff Dorothy Benton Alison M. Kurimchak Daniela Araiza-Olivera Anastasiia Gerasimova Nathaniel W. Snyder James S. Duncan Cristina Uribe-Alvarez Jonathan Chernoff KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation Cell Reports CP: Cancer |
| title | KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation |
| title_full | KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation |
| title_fullStr | KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation |
| title_full_unstemmed | KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation |
| title_short | KRAS G12V mutation-selective requirement for ACSS2 in colorectal adenoma formation |
| title_sort | kras g12v mutation selective requirement for acss2 in colorectal adenoma formation |
| topic | CP: Cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2211124725002153 |
| work_keys_str_mv | AT konstantinbudagyan krasg12vmutationselectiverequirementforacss2incolorectaladenomaformation AT alexaccannon krasg12vmutationselectiverequirementforacss2incolorectaladenomaformation AT adamchatoff krasg12vmutationselectiverequirementforacss2incolorectaladenomaformation AT dorothybenton krasg12vmutationselectiverequirementforacss2incolorectaladenomaformation AT alisonmkurimchak krasg12vmutationselectiverequirementforacss2incolorectaladenomaformation AT danielaaraizaolivera krasg12vmutationselectiverequirementforacss2incolorectaladenomaformation AT anastasiiagerasimova krasg12vmutationselectiverequirementforacss2incolorectaladenomaformation AT nathanielwsnyder krasg12vmutationselectiverequirementforacss2incolorectaladenomaformation AT jamessduncan krasg12vmutationselectiverequirementforacss2incolorectaladenomaformation AT cristinauribealvarez krasg12vmutationselectiverequirementforacss2incolorectaladenomaformation AT jonathanchernoff krasg12vmutationselectiverequirementforacss2incolorectaladenomaformation |